

SUPPLEMENTARY FILE

Effect of Empagliflozin on plasma lipids and lipoproteins in type 2 diabetes and heart failure – Empire HF and SIMPLE

Frida Emanuelsson¹, Jesper Jensen², Massar Omar^{3,4}, Mikkel Jürgens⁵, Caroline Kistorp^{6,8}, Niels H. Brandt-Jacobsen^{5,8}, Jacob Eifer Møller^{3,6}, Morten Schou^{2,8}, Louise Ellegaard Bechmann¹, Emil List Larsen¹, Børge G. Nordestgaard^{7,8}, Marianne Benn^{1,8}


¹Department of Clinical Biochemistry, Copenhagen University Hospital - Rigshospitalet, Centre of Diagnostic Investigation, Copenhagen, Denmark; ²Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark; ³Department of Cardiology, Odense University Hospital, Odense, Denmark; ⁴Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark. ⁵Department of Endocrinology, Copenhagen University Hospital – Rigshospitalet, Centre for Cancer and Organ Diseases, Copenhagen, Denmark; ⁶Clinical Institute, University of Southern Denmark, Odense, Denmark. ⁷Department of Clinical Biochemistry, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark; and ⁸Faculty of Health and Medical Sciences, Department of Clinical Medicine, University of Copenhagen, Denmark.

Content

Supplementary Figure 1	2
Supplementary Figure 2	3
Supplementary Figure 3	4


Supplementary Figure 1

LDL cholesterol measured directly vs. calculated



Scatterplot with a fitted regression line from an unadjusted linear regression. To convert cholesterol concentration in mmol/L to mg/dL, multiply by 38.6. LDL = Low density lipoprotein, P = Plasma.


Supplementary Figure 2



Effect of empagliflozin on calculated and direct plasma low density lipoprotein (LDL) cholesterol concentrations. Left panels show mean absolute changes from baseline to the primary analysis time point at 90 days and right panels percent change in the Empire HF trial with participants receiving 10 mg daily of empagliflozin (dark blue bars) or placebo (light blue bars), the SIMPLE trial with participants receiving 25 mg daily of empagliflozin (dark blue bars) or placebo (light blue bars), and in the two studies combined. Error bars denote standard error of the mean. P values are from analyses of covariance.

Supplementary Figure 3

Triglyceride rich lipoprotein cholesterol vs. VLDL cholesterol



Scatterplot with a fitted regression line from an unadjusted linear regression. To convert cholesterol concentration in mmol/L to mg/dL, multiply by 38.6. VLDL = Very low density lipoprotein, P = Plasma.